UroGen Pharma Ltd. (NASDAQ:URGN) Receives $38.20 Average PT from Analysts
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target […]
Shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) have received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target […]
